| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 24 | 2023 | 2992 | 2.180 |
Why?
|
| Drug Hypersensitivity | 4 | 2023 | 128 | 1.880 |
Why?
|
| Fever | 6 | 2020 | 497 | 1.780 |
Why?
|
| Antimicrobial Stewardship | 3 | 2022 | 84 | 1.690 |
Why?
|
| Typhus, Endemic Flea-Borne | 2 | 2020 | 19 | 1.410 |
Why?
|
| Gentamicins | 4 | 2018 | 90 | 1.380 |
Why?
|
| Candidemia | 4 | 2023 | 60 | 1.130 |
Why?
|
| Metagenomics | 2 | 2022 | 115 | 0.970 |
Why?
|
| Fever of Unknown Origin | 2 | 2016 | 63 | 0.950 |
Why?
|
| Candida | 3 | 2014 | 164 | 0.910 |
Why?
|
| Exanthema | 3 | 2020 | 211 | 0.880 |
Why?
|
| Sepsis | 4 | 2023 | 652 | 0.870 |
Why?
|
| Blood Culture | 1 | 2022 | 32 | 0.850 |
Why?
|
| Candidiasis, Invasive | 3 | 2023 | 22 | 0.850 |
Why?
|
| Outpatients | 3 | 2023 | 462 | 0.830 |
Why?
|
| Enterobacter | 1 | 2021 | 20 | 0.830 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 390 | 0.810 |
Why?
|
| Meningitis | 2 | 2019 | 112 | 0.800 |
Why?
|
| Pediatrics | 4 | 2020 | 1141 | 0.800 |
Why?
|
| Child | 36 | 2023 | 29154 | 0.790 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 69 | 0.790 |
Why?
|
| Angiostrongylus cantonensis | 2 | 2018 | 9 | 0.750 |
Why?
|
| Strongylida Infections | 2 | 2018 | 15 | 0.740 |
Why?
|
| Respiratory Tract Infections | 2 | 2023 | 437 | 0.730 |
Why?
|
| Rickettsia typhi | 1 | 2019 | 12 | 0.700 |
Why?
|
| Antifungal Agents | 5 | 2023 | 834 | 0.700 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 671 | 0.700 |
Why?
|
| Ideal Body Weight | 1 | 2018 | 8 | 0.660 |
Why?
|
| Headache | 1 | 2019 | 163 | 0.650 |
Why?
|
| Bacteremia | 3 | 2021 | 689 | 0.640 |
Why?
|
| Infant | 19 | 2022 | 13310 | 0.630 |
Why?
|
| Pneumonia | 2 | 2023 | 751 | 0.620 |
Why?
|
| Urinary Tract Infections | 3 | 2016 | 321 | 0.600 |
Why?
|
| Eye Infections, Viral | 1 | 2016 | 30 | 0.570 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 2291 | 0.530 |
Why?
|
| Child, Preschool | 17 | 2022 | 16273 | 0.530 |
Why?
|
| Culturally Competent Care | 1 | 2015 | 42 | 0.510 |
Why?
|
| Child Health | 1 | 2015 | 54 | 0.500 |
Why?
|
| Penicillins | 4 | 2023 | 143 | 0.500 |
Why?
|
| Tropical Medicine | 1 | 2015 | 105 | 0.480 |
Why?
|
| Electronic Health Records | 1 | 2022 | 929 | 0.470 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 446 | 0.460 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 2 | 2003 | 25 | 0.460 |
Why?
|
| Leukemia | 1 | 2021 | 1635 | 0.430 |
Why?
|
| Neglected Diseases | 1 | 2015 | 147 | 0.430 |
Why?
|
| Obesity | 2 | 2018 | 2884 | 0.430 |
Why?
|
| Humans | 61 | 2023 | 261506 | 0.420 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 489 | 0.410 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 294 | 0.410 |
Why?
|
| Adolescent | 19 | 2022 | 31252 | 0.400 |
Why?
|
| Amphotericin B | 1 | 2012 | 289 | 0.390 |
Why?
|
| Serum | 1 | 2011 | 68 | 0.380 |
Why?
|
| Simplexvirus | 1 | 2011 | 159 | 0.370 |
Why?
|
| Herpes Simplex | 1 | 2011 | 95 | 0.360 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 748 | 0.360 |
Why?
|
| Global Health | 1 | 2015 | 657 | 0.360 |
Why?
|
| Cross Infection | 3 | 2021 | 544 | 0.360 |
Why?
|
| Male | 30 | 2022 | 123000 | 0.330 |
Why?
|
| Primary Health Care | 3 | 2023 | 787 | 0.310 |
Why?
|
| Inappropriate Prescribing | 2 | 2020 | 50 | 0.300 |
Why?
|
| Bacterial Infections | 3 | 2023 | 479 | 0.300 |
Why?
|
| Brucella melitensis | 1 | 2007 | 7 | 0.300 |
Why?
|
| Retrospective Studies | 17 | 2023 | 37905 | 0.300 |
Why?
|
| Brucellosis | 1 | 2007 | 14 | 0.300 |
Why?
|
| Fetal Diseases | 1 | 2011 | 388 | 0.300 |
Why?
|
| Neutropenia | 1 | 2011 | 968 | 0.290 |
Why?
|
| Streptococcus agalactiae | 2 | 2005 | 107 | 0.290 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 598 | 0.280 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 419 | 0.280 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 128 | 0.280 |
Why?
|
| Cough | 1 | 2007 | 116 | 0.270 |
Why?
|
| Cohort Studies | 8 | 2023 | 9244 | 0.260 |
Why?
|
| Internship and Residency | 2 | 2018 | 1375 | 0.260 |
Why?
|
| Female | 27 | 2022 | 141928 | 0.260 |
Why?
|
| Streptococcal Vaccines | 1 | 2004 | 17 | 0.250 |
Why?
|
| Enterococcus faecalis | 2 | 2014 | 49 | 0.250 |
Why?
|
| Vaccines, Conjugate | 1 | 2004 | 76 | 0.240 |
Why?
|
| Enterobacteriaceae | 2 | 2014 | 46 | 0.240 |
Why?
|
| Osteomyelitis | 1 | 2007 | 236 | 0.240 |
Why?
|
| Antibodies, Bacterial | 2 | 2005 | 380 | 0.220 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 698 | 0.220 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 4744 | 0.210 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 68 | 0.210 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2014 | 233 | 0.210 |
Why?
|
| Philadelphia | 1 | 2022 | 38 | 0.210 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2003 | 76 | 0.210 |
Why?
|
| Cephalosporins | 2 | 2020 | 148 | 0.210 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 43 | 0.200 |
Why?
|
| Texas | 4 | 2020 | 6311 | 0.190 |
Why?
|
| Shock, Septic | 1 | 2023 | 181 | 0.190 |
Why?
|
| Risk Factors | 8 | 2023 | 17523 | 0.190 |
Why?
|
| Skin Tests | 1 | 2021 | 96 | 0.190 |
Why?
|
| Myalgia | 1 | 2020 | 13 | 0.190 |
Why?
|
| Community-Acquired Infections | 1 | 2023 | 285 | 0.190 |
Why?
|
| Disease Vectors | 1 | 2020 | 27 | 0.190 |
Why?
|
| Hypersensitivity | 1 | 2023 | 216 | 0.190 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2002 | 238 | 0.180 |
Why?
|
| Feedback | 1 | 2020 | 198 | 0.180 |
Why?
|
| Photophobia | 1 | 2019 | 10 | 0.180 |
Why?
|
| Curriculum | 2 | 2015 | 860 | 0.180 |
Why?
|
| Immunization | 1 | 2021 | 397 | 0.170 |
Why?
|
| Doxycycline | 1 | 2020 | 178 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2022 | 193 | 0.170 |
Why?
|
| Teaching | 2 | 2012 | 243 | 0.160 |
Why?
|
| Prednisone | 2 | 2016 | 984 | 0.160 |
Why?
|
| Teicoplanin | 1 | 2017 | 6 | 0.160 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 129 | 0.150 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.150 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 672 | 0.150 |
Why?
|
| Eye Hemorrhage | 1 | 2016 | 3 | 0.150 |
Why?
|
| Clostridium Infections | 1 | 2020 | 252 | 0.150 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 12 | 0.150 |
Why?
|
| Ecchymosis | 1 | 2016 | 21 | 0.150 |
Why?
|
| Choice Behavior | 1 | 2018 | 226 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2023 | 441 | 0.140 |
Why?
|
| Conjunctival Diseases | 1 | 2016 | 37 | 0.140 |
Why?
|
| Infant, Newborn | 9 | 2015 | 8223 | 0.140 |
Why?
|
| Education, Medical | 2 | 2012 | 331 | 0.140 |
Why?
|
| Educational Measurement | 1 | 2018 | 362 | 0.140 |
Why?
|
| Macrolides | 1 | 2016 | 62 | 0.140 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 81 | 0.140 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2011 | 427 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2016 | 193 | 0.140 |
Why?
|
| Orbital Diseases | 1 | 2016 | 118 | 0.130 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 87 | 0.130 |
Why?
|
| Program Evaluation | 2 | 2015 | 597 | 0.130 |
Why?
|
| Rat-Bite Fever | 1 | 2014 | 4 | 0.130 |
Why?
|
| Streptobacillus | 1 | 2014 | 4 | 0.130 |
Why?
|
| Infant, Premature, Diseases | 2 | 2009 | 245 | 0.130 |
Why?
|
| Edema | 1 | 2016 | 267 | 0.130 |
Why?
|
| Coagulase | 2 | 2012 | 29 | 0.120 |
Why?
|
| Drug Resistance, Fungal | 1 | 2014 | 92 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2016 | 176 | 0.120 |
Why?
|
| Specialization | 1 | 2015 | 130 | 0.120 |
Why?
|
| HIV Infections | 1 | 2007 | 2134 | 0.120 |
Why?
|
| Arthralgia | 1 | 2014 | 89 | 0.120 |
Why?
|
| Staphylococcus | 2 | 2012 | 86 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 851 | 0.120 |
Why?
|
| Students, Medical | 1 | 2018 | 399 | 0.110 |
Why?
|
| Chemoprevention | 2 | 2011 | 241 | 0.110 |
Why?
|
| Antiviral Agents | 2 | 2011 | 1230 | 0.110 |
Why?
|
| Hypokalemia | 1 | 2012 | 55 | 0.110 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 117 | 0.110 |
Why?
|
| Critical Pathways | 1 | 2013 | 149 | 0.110 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2012 | 35 | 0.100 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2012 | 273 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1303 | 0.100 |
Why?
|
| Equipment Contamination | 1 | 2012 | 90 | 0.100 |
Why?
|
| Triazoles | 1 | 2016 | 617 | 0.100 |
Why?
|
| Culture Media | 1 | 2012 | 319 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 5687 | 0.100 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 181 | 0.100 |
Why?
|
| Appendicitis | 1 | 2013 | 169 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2018 | 1270 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 418 | 0.090 |
Why?
|
| Infant, Premature | 3 | 2011 | 787 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 4938 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 231 | 0.090 |
Why?
|
| Half-Life | 1 | 2010 | 259 | 0.090 |
Why?
|
| United States | 7 | 2018 | 15433 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 622 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 698 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.090 |
Why?
|
| Hip Joint | 1 | 2009 | 54 | 0.090 |
Why?
|
| Arthritis, Infectious | 1 | 2009 | 68 | 0.080 |
Why?
|
| Eye | 1 | 2011 | 301 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 354 | 0.080 |
Why?
|
| Shoulder Joint | 1 | 2009 | 82 | 0.080 |
Why?
|
| Medical Records | 1 | 2010 | 415 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2011 | 436 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2307 | 0.080 |
Why?
|
| Clinical Medicine | 1 | 2008 | 24 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2009 | 250 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 4367 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 691 | 0.070 |
Why?
|
| Elbow Joint | 1 | 2007 | 42 | 0.070 |
Why?
|
| Sternum | 1 | 2007 | 100 | 0.070 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 163 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2009 | 498 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2007 | 130 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2015 | 6100 | 0.070 |
Why?
|
| Young Adult | 2 | 2021 | 21445 | 0.070 |
Why?
|
| Skin | 1 | 2011 | 1259 | 0.060 |
Why?
|
| Animals | 3 | 2020 | 59536 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2017 | 700 | 0.060 |
Why?
|
| Diphtheria-Tetanus Vaccine | 1 | 2004 | 3 | 0.060 |
Why?
|
| Streptococcal Infections | 2 | 2005 | 280 | 0.060 |
Why?
|
| Tetanus Toxoid | 1 | 2004 | 43 | 0.060 |
Why?
|
| Carrier State | 1 | 2005 | 90 | 0.060 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2004 | 67 | 0.060 |
Why?
|
| Serotyping | 1 | 2004 | 166 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 147 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3472 | 0.060 |
Why?
|
| Antibody Specificity | 1 | 2004 | 334 | 0.060 |
Why?
|
| Aging | 2 | 2010 | 1582 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2004 | 266 | 0.060 |
Why?
|
| Pneumocystis | 1 | 2002 | 13 | 0.060 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 355 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2014 | 12873 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2002 | 72 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 210 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 180 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2014 | 32848 | 0.050 |
Why?
|
| Infectious Disease Medicine | 1 | 2022 | 20 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 77950 | 0.050 |
Why?
|
| Incidence | 1 | 2011 | 5673 | 0.050 |
Why?
|
| Models, Econometric | 2 | 2011 | 13 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 548 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2330 | 0.050 |
Why?
|
| Palivizumab | 2 | 2011 | 64 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 7702 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 416 | 0.040 |
Why?
|
| Prevalence | 2 | 2023 | 3260 | 0.040 |
Why?
|
| Aspirin | 1 | 2003 | 455 | 0.040 |
Why?
|
| Patient Safety | 2 | 2016 | 649 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 978 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 754 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 2588 | 0.040 |
Why?
|
| Research | 1 | 2020 | 415 | 0.040 |
Why?
|
| Pregnancy | 1 | 2011 | 7573 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 2315 | 0.040 |
Why?
|
| Time Factors | 1 | 2011 | 12926 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 485 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2016 | 21 | 0.030 |
Why?
|
| Logistic Models | 1 | 2023 | 3441 | 0.030 |
Why?
|
| Logic | 1 | 2015 | 10 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 29902 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2018 | 289 | 0.030 |
Why?
|
| Vaccination | 1 | 2021 | 1123 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 95 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 4314 | 0.030 |
Why?
|
| Biopsy | 1 | 2003 | 3443 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 860 | 0.030 |
Why?
|
| Government Regulation | 1 | 2013 | 67 | 0.030 |
Why?
|
| Teaching Materials | 1 | 2012 | 21 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 60 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 4320 | 0.030 |
Why?
|
| Appendectomy | 1 | 2013 | 124 | 0.030 |
Why?
|
| Program Development | 1 | 2013 | 261 | 0.030 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 118 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 4971 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 156 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 1529 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 6150 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2013 | 333 | 0.020 |
Why?
|
| Infection Control | 1 | 2013 | 270 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 323 | 0.020 |
Why?
|
| Budgets | 1 | 2011 | 25 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 649 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 994 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 241 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2003 | 6869 | 0.020 |
Why?
|
| Health Policy | 1 | 2013 | 291 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3890 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 450 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 3251 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 2083 | 0.020 |
Why?
|
| Aged | 3 | 2018 | 70117 | 0.020 |
Why?
|
| Drainage | 1 | 2009 | 416 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 918 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 1900 | 0.020 |
Why?
|
| Prognosis | 1 | 2003 | 21713 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2009 | 945 | 0.020 |
Why?
|
| Neoplasms | 1 | 2011 | 15193 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 237 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 204 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2005 | 347 | 0.010 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2004 | 165 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 1375 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 2403 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 210 | 0.010 |
Why?
|
| Vancomycin | 1 | 2004 | 273 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 827 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 443 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 374 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 1069 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 1021 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5542 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 4298 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 86204 | 0.010 |
Why?
|